XML 53 R36.htm IDEA: XBRL DOCUMENT v3.22.4
COMMERCIALIZATION AGREEMENTS (Details) - USD ($)
1 Months Ended 12 Months Ended
Mar. 29, 2021
Mar. 16, 2020
Sep. 30, 2020
Mar. 31, 2020
Jul. 23, 2018
Oct. 19, 2017
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Jun. 30, 2021
May 13, 2021
Oct. 31, 2015
Nov. 30, 2009
Payment for promissory note             $ 0 $ 4,086,000 $ 215,000        
Pfizer                          
Collaborative Arrangement Profit Share Percentage                         40.00%
Debt Instrument, Face Amount                       $ 4,300,000  
Promissory note     $ 4,300,000                    
Payment on notes payable     $ 430,000                    
Payment for promissory note $ 4,000,000.0                        
Chiesi US Agreement and Chiesi Ex-US Agreement                          
Non-refundable Payment Receivable         $ 25,000,000.0 $ 25,000,000.0 50,000,000.0            
Agreement Amendment Payment Receivable             10,000,000.0     $ 10,000,000.0      
Payments in consideration for development services performed             45,000,000.0            
Payments in connection with performance of additional studies             48,700,000            
Recognized revenues related to non-refundable payment             1,200,000 600,000 3,500,000        
Future milestone payment             10,000,000.0 $ 10,000,000.0 $ 10,000,000.0        
Chiesi US Agreement                          
Non-refundable Payment Receivable         25,000,000.0                
Additional Amounts Payable To Cover Development Costs         20,000,000.0                
Maximum Entitlement Of Development Costs To Cover Per Year         7,500,000                
Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones         $ 760,000,000.0   $ 735,000,000.0            
Chiesi US Agreement | Maximum                          
Payment On Net Sales Percentage         40.00%   40.00%            
Chiesi US Agreement | Minimum                          
Payment On Net Sales Percentage         15.00%   15.00%            
Chiesi Ex-US Agreement                          
Non-refundable Payment Receivable           25,000,000.0              
Additional Amounts Payable To Cover Development Costs           25,000,000.0              
Maximum Entitlement Of Development Costs To Cover Per Year           10,000,000.0              
Agreement Amendment Payment Receivable                     $ 10,000,000.0    
Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones           $ 320,000,000.0              
Chiesi Ex-US Agreement | Maximum                          
Payment On Net Sales Percentage           35.00% 35.00%            
Chiesi Ex-US Agreement | Minimum                          
Payment On Net Sales Percentage           15.00% 15.00%            
Kirin Holdings Company, Limited [Member]                          
Recognized revenues related to non-refundable payment       $ 1,000,000.0                  
Non-Refundable Future Service Payment   $ 1,000,000.0